AbbVie Inc., based in North Chicago, specializes in pharmaceuticals worldwide, focusing on immunology, oncology, aesthetics, neuroscience, and eye care. The company is set to announce its fiscal fourth-quarter earnings for 2025. Analysts predict a profit of $3.37 per share, a 56% increase from the previous year.

For the full year, analysts expect AbbVie to report an EPS of $10.65, up 5.2% from the previous fiscal year. The company’s EPS is projected to rise by 35.4% year over year to $14.42 in fiscal 2026. AbbVie stock has outperformed the S&P 500 Index and the Health Care Select Sector SPDR Fund over the past 52 weeks.

AbbVie’s success is attributed to products like Skyrizi and Rinvoq, acquisitions, and manufacturing expansions. Despite aesthetic challenges, the company’s focus on immunology and neuroscience drives growth. After reporting Q3 results, AbbVie shares closed down by 4.5% but still beat Wall Street expectations.

Analysts hold a moderately bullish view on AbbVie stock, with a “Moderate Buy” rating overall. Out of 28 analysts covering the stock, 16 suggest a “Strong Buy,” one advises a “Moderate Buy,” and 11 recommend a “Hold.” The average analyst price target is $245.81, indicating a potential upside of 7.6% from current levels.

Read more at Yahoo Finance: What to Expect From AbbVie’s Next Quarterly Earnings Report